He once waited 5 hours in the rain so his daughter could see her favorite band. Imagine what he’ll do now that the stakes are higher.
The final analyses of KEYNOTE-189 are in. There’s updated overall survival (OS) data for ALIMTA + KEYTRUDA® (pembrolizumab) with platinum.SEE IT NOW
ALIMTA is indicated in combination with pembrolizumab (pembro) and platinum chemotherapy for the initial treatment of patients with nonsquamous metastatic non-small cell lung cancer (mNSCLC) with no EGFR or ALK genomic tumor aberrations.
Limitation of Use: ALIMTA is not indicated for the treatment of patients with squamous cell non-small cell lung cancer.
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.6.2020. © National Comprehensive Cancer Network, Inc 2020. All rights reserved. Accessed June 16, 2020. To view the most recent and complete version of the guidelines, go online to NCCN.org . NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
- ALIMTA (pemetrexed for injection) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.